Inactive Instrument

News Biocorrx Inc Other OTC

Stocks

US09073C1062

Healthcare Facilities & Services

All News

05-15	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-31	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	BioCorRx Inc. Auditor Raises 'Going Concern' Doubt	CI
01-06	BioCorRx Inc. Announces Board Changes, Effective January 1, 2026	CI
12-10	BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th	AQ
11-14	BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-14	BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-07-28	BioCorRx Inc. announced that it has received $0.35 million in funding	CI
25-05-15	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-31	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-03-30	BioCorRx Inc. Auditor Raises 'Going Concern' Doubt	CI
24-11-14	BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-08-15	BioCorRx Reports Business Update for the Second Quarter of 2024	AQ
24-08-13	BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-05-16	BioCorRx Reports Business Update for the First Quarter of 2024	AQ
24-05-15	BioCorRx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-04-03	BioCorRx Inc. Announces Board Resignations	CI
24-04-03	BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia	AQ
24-04-02	BioCorRx Reports Business Update for 2023	AQ
24-04-01	BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-03-31	BioCorRx Inc. Auditor Raises 'Going Concern' Doubt	CI
24-02-28	BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD	AQ
24-02-08	BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors	AQ
24-02-08	BioCorRx Pharmaceuticals Inc. Appoints Kate Devarney to the Board of Directors	CI
24-01-09	BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President	AQ